Skip to Content

Adaptive Designs and Endpoint Strategy in Cardiovascular Trials

Practical Tradeoffs and Lessons Learned
April 13, 2026 by
Cardiovascular Clinical Science
A practical discussion with Bioforum on adaptive and Bayesian trial designs and the endpoint choices that can make or break cardiovascular studies — covering tradeoffs and lessons learned across time-to-event, event-count, composite endpoints, and win ratio, followed by live Q&A. Free to watch.


Featured Presenters


Marvin A. Konstam, MD

Chief Scientific Officer, Cardiovascular Clinical Science Professor of Medicine and Radiology, Tufts University School of Medicine.

An internationally recognized leader in heart failure research and cardiovascular drug and device development, Dr. Konstam founded CCS in 1997 and has guided companies and investigators through every stage of clinical research for more than 30 years, integrating scientific rigor with regulatory expectations. He also served as Chief Physician Executive of the Cardiovascular Center at Tufts Medical Center. A graduate of Columbia University with further training at Massachusetts General Hospital, Brigham and Women's Hospital, and Harvard Medical School, he has played a central role in pioneering research on ventricular remodeling and in numerous cardiovascular clinical trials — including work shaping the statistical and methodological approaches used to evaluate cardiovascular therapies. His regulatory involvement includes service on the FDA's Cardiovascular and Renal Advisory Panel and advisory work with CMS on evidence development and heart-failure quality-of-care initiatives.

Zoran Antonijevic

Chief Scientific Officer, Bioforum The Data Masters

 Zoran has held executive positions at pharmaceutical companies and CROs and has designed more than 100 clinical trials across numerous therapeutic areas, many with innovative designs. He was a long-time Chair of the DIA Innovative Design Scientific Working Group, and is co-editor of Optimization of Pharmaceutical R&D Programs and Portfolios and, with Bob Beckman, Platform Trials in Drug Development.